Lv3
328 积分 2022-03-14 加入
A Bayesian network meta-analysis regarding the comparative efficacy of therapeutics for ALK-positive, brain metastatic non-small cell lung cancer
7天前
已完结
Comparison of lorlatinib, alectinib and brigatinib in ALK inhibitor–naive/untreated ALK-positive advanced non-small-cell lung cancer: a systematic review and network meta-analysis
7天前
已完结
Crizotinib versus Alectinib for the Treatment of ALK-Positive Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
7天前
已完结
Efficacy and safety of ALK inhibitors in ALK-rearranged non-small cell lung cancer: A systematic review and meta-analysis
7天前
已完结
ALK inhibitor-induced bradycardia: A systematic-review and meta-analysis
7天前
已完结
Brigatinib Versus Crizotinib in ALK Inhibitor–Naive Advanced ALK-Positive NSCLC: Final Results of Phase 3 ALTA-1L Trial
9天前
已完结
TRI-611, a selective, brain-penetrant molecular glue degrader of ALK
9天前
已完结
Cancer burden and control in China: landscape, trends and challenges
21天前
已完结
First-Line Lorlatinib or Crizotinib in Advanced ALK -Positive Lung Cancer
22天前
已完结
First-line ceritinib versus platinum-based chemotherapy in advanced ALK -rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 study
28天前
已完结
皖公网安备34019202002308
